ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0729

Factors Associated with Pauci-immune Glomerulonephritis in Patients Undergoing Renal Biopsy with Positive ANCA Results

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0722

Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0538

Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0436

Family Planning in Rheumatology: A Single Center Quality Improvement Project

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0352

Fast-tracking Axial Spondyloarthritis Diagnosis: A Novel Approach to Public Health Advocacy and Awareness

Patient Education/Community Programs Poster – ARP

10:30AM-12:30PM: Abstract Number: 0053

Fasting Reduces an IL-17+/IFNg+ T Helper Cell-inducing Gut Pathobiont in Patients with Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30AM: Abstract Number: PP09

Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS

Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0057

Flow Cytometry of Cells Within Induced Sputum from Individuals At-Risk for RA Reveals Relative Expansion of Small Macrophages

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0059

Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0153

Frequencies and Rates of All-Cause Emergency Visits and Hospitalizations in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0578

Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0571

Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0628

Genetic Determinants of Childhood Onset Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0549

Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0226

Global Ultrasound Scoring Systems for Assessing Synovitis in Rheumatoid Arthritis

Imaging of Rheumatic Diseases Poster I: Inflammatory Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].